Objectives: To evaluate the mortality after treatment with a paclitaxel (PTX)-coated device
and with uncoated devices of iliac, femoropopliteal, and below-the-knee lesions in dialysis …

Purpose: To report the risk of all-cause mortality in patients who underwent dialysis access
treatment using paclitaxel-coated devices compared with percutaneous transluminal …

Objective Long-term safety concerns have been raised that the use of paclitaxel-coated
balloons and stents is linked to excess mortality. Our objective was to compare outcomes in …

Objective This observational cohort study examined outcomes after peripheral vascular
intervention (PVI) with paclitaxel coated devices (PCD) and non-PCD, and evaluated …

Objective Long-term safety concerns were recently raised by a meta-analysis that reported
increased mortality after the use of paclitaxel (PTX)-coated balloons and stents. This report …

Background According to a meta-analysis of randomized clinical trials, paclitaxel-coated
devices (PCDs) for lower limb endovascular revascularization may be associated with …

A recent meta-analysis addressed increased risk of death following revascularization with
paclitaxel-coated devices in femopopliteal artery. We evaluated differences in all-cause …

Mortality with Paclitaxel-Coated Devices in Peripheral Artery Disease Page 1 greater risk of
stroke compared with patients with 70% to 80% stenosis, but patients with less than 50 …

Objective Data regarding the safety and efficacy of paclitaxel (PTX)-coated peripheral
arterial devices for femoropopliteal artery (FPA) atherosclerotic disease is derived from …

Objective Paclitaxel (PTX)-coated peripheral arterial devices have been shown to decrease
femoropopliteal artery restenosis and the need for reintervention compared with non-PTX …